important to analyze the profitability and the portfolio risk. The evolution of the stock prices included in the portfolio can influence the overall portfolio profitability. A major risk of a single share can bring a surplus of risk to the overall portfolio.
I. INTRODUCTION
The investment decision requires a rigorous analysis of the financial instruments. Based on this analysis it seeks to determine the correct price of financial assets and to evaluate them. Starting from the theory developed by Markowitz, W., Sharpe (1964) [1] found a link between a financial asset's profitability and the market portfolio's return. His model, Capital Asset Pricing Model, represents a crucial step in the evaluation of the primary financial instruments. Therefore, this paper will analyze unifactorial models of the primary financial instruments assessment (CAPM).
The CAPM was developed independently by W., Sharpe (1963 Sharpe ( , 1964 , J., Treynor (1961) [2] , J., Mossin (1966) [3] , and J., Lintner (1965 Lintner ( , 1969 [4] . This model succeeded in highlighting a relationship between a financial asset's profitability and the return of a fully diversified portfolio. Later, the literature has widely studied this phenomenon. Later, the CAPM model was widely used to analyze the asset pricing such as J., H., Cochrane (2001) [5] or the market inefficiency like L. A. Stout (2002 Stout ( -2003 [6] or the risk premia as M. Lettau and S. Ludvigson (2001) [7] . The most recently works have studied the market risks like A., Carol (2008) [8] , the adequate portfolio and investment decision management like A. V., Rutkauskas, V. Stasytyte, and J., Borisova (2009) [9] , the investment decision modeling as A. V., Rutkauskas, A., Miečinskienė (2008) , and V., Stasytytė [10] did, portofolio with free-risk asset like F. Serban, M. V. Stefanescu and S. Dedu (2011) [11] or investments during financial the crisis as M. C., Stefan (2012) [12] In order to achieve the case study, monthly indicators (from January 2006 to August 2013) for the stock returns have been used. The scope is to capture short-term portfolio variations on the Romanian pharmaceutical market from the early stages of the current global financial crisis to present. Stock yields were obtained based on closing prices.
III. ESTIMATION OF INDICATORS AND INTERPRETATION OF RESULTS
In the econometric analysis, in order to obtain valid results, the outline is removed and its value is replaced with the average yield of each share. Thus, the series have been adjusted. In all graphs, the CAPM model is used after eliminating the outline. As is shown in Fig. 1 , theoretically, it is made the assumption that the market portfolio includes all risky assets existing on capital markets. In fact, in practice it is difficult to estimate the price of a hybrid portfolio that includes stocks, bonds, mortgages, etc.. For this reason, an index that reflects the overall market tendency or the market performance is used as a proxy for the market portfolio. For example, for the Romanian capital market BET-C index has been used as a proxy. BET-C includes the price evolution of all companies listed on the Bucharest Stock Exchange regulated market, Category I and II, except for SIFs.
Being the risk distinction in the market risk (systematic) and specific risk (unsystematic), the factorial models try to explain these two risk components.
So, the market model (having one parameter), which estimates the CAPM model equation, has the following form:
where E(R i ) = risky financial asset return; (rf) = risk-free asset return, E(R M ) = market portfolio return, (E(RM)-rf) = market risk premium adjusted with a beta indicator specific for each action, α = constant (intercept), β = market risk component and indicates the sensitivity of the asset i return to the return of the market portfolio, ε = specific risk component, diversified, encompassing random events that affect a share, and is actually the regression residue. The CAPM ("Capital Assets Pricing Model") model result described in the above relations is very important. Formulas indicate the relationship between a risky financial asset return and the return of a fully diversified portfolio through the risk indicator beta (β).
In other words, the indicator beta for a specific share is the risk excess brought to a well-diversified portfolio caused by one percentage point weight increasing for this share.
IV. TESTING THE SIGNIFICANCE OF THE REGRESSION MODEL PARAMETERS

A. The Student Test
As a result of the parameters estimation, each share reacts differently from the market portfolio and has specific characteristics.
Therefore, in the case of the ATB share, statistically we can state the following, as shown in the figure below: α (intercept = c) registers a P-value of 0,4355 > 0,05 (where 5% is the fixed significance threshold, for α=95% (prob = 1-α = 0,95), which means that α is not significantly different from 0 (the regression model is not correctly specified); and β (BETC_YIELD) records a probability of 0,0000 < 0,05 (see Fig. 2 ), I mean with a probability of 95% β is significantly different from zero. The same thing happens in the case of BIO, RMAH, SCD and MEDU, whose estimated coefficients are significant statistically. On the other hand, we cannot say the same thing about FAMD, FITO and SINT shares, because the probability value associated with each coefficient is greater than the significance threshold of 5%, as you can see in Table  I .
B. Risk and Yield Coefficients
Alpha coefficient (α) represents the difference between the current average return and the forecast average return. In general, we can say that an α equal to zero highlights an asset to be properly evaluated. Usually, the values of α are less than one. A positive α indicates that the financial asset is undervalued, while a negative α indicates that financial asset is overvalued. According to the estimates, the values presented in Table I , we can talk about a overvaluation only in the case of the ATB, the rest of the shares are undervalued.
Beta coefficient (β) (BET-C index) is the systematic risk indicator and measures the sensitivity of the shares on the market, I mean the expected average return. If it is greater than 1, it reacts more aggressive than the market portfolio, and if it is less than 1, it reacts weaker than the market portfolio.
According to Table I , the β coefficient value < 1, so the entire portfolio of shares, made up of the most important and significant companies of the pharmaceutical sector, reacts weaker than market portfolio (has a low risk).
The specific risk of each share is also represented by means of S.E. of the regression indicator and, according 
C. Testing the Stability of the Estimated β Coefficient by the Market Model -Wald Test
The coefficient β (BET-C index) estimated by the market model is quite significant for the market, the Romanian pharmaceutical market respectively, but its stability must be tested, as a necessary and mandatory condition. Therefore, in order to achieve a properly specified model and obtaining valid results, we tested the stability of the β coefficient using the Wald test, as Fig. 3 shows (see also Table I ). It can be seen that the probability associated with the Wald test, represented by F-statistic, exceeds the significance threshold of 5% only in the case of MEDU share (see Table  I ). Thus the recorded estimated value is 0,8438 > 0,05. Hence it follows that we cannot reject the null hypothesis, so the restriction imposed to the parameters is valid. Relating to the rest of the shares from the portfolio (see Table I ), the probability of the Wald test is situated below the significance threshold of 5%, for which reason we reject the null hypothesis.
Another indicator, which helps to express the correlation between the variables included in this model, is the report of determination, R-squared, as well as its derivative, Adjusted R-squared. In most cases, the values of the Adjusted R-squared coefficient are more relevant than the values of the R-squared determination coefficient (shows the percentage in a more accurate form) and we will analyze its values, although the difference between them is not very large.
Thus, in the case of the ATB, the Adjusted R-Square is 0,2539 which means that 25,39% of the variation of the ATB portfolio return is explained on the basis of the portfolio market variation. (R-squared is 0,2622). Relative to the expansion to other representative shares on the Romanian pharmaceutical market, for the period from January 2006 to August 2013, we can state that a percentage of 33,06% of the variation of BIO portfolio return; 7,69% of the variation of RMAH portfolio return; 21,49% of the variation of SCD portfolio return; -1,05% of the variation of FAMD portfolio return, -1% of the variation of FITO portfolio return; 9,98% of the variation of MEDU portfolio return and, respectively,-0,35% of the variation of SINT portfolio return, is explained on the basis of portfolio market variation. As you can see, there are significant differences between these values, the most receptive to the market`s changes, the company listed on the Bucharest Stock Exchange, is that one whose symbol is BIO, Biofarm S.A. respectively.
D. Testing Residue Normality -Jarque-Bera test
The Jarque-Bera test (see Fig. 4 ) also plays a very important role in assessing the validity of the model and data used. It allows the simultaneous testing of the asymmetry and flattening particularities of the residuals series and examines how the empirical distribution can be approximated by a normal distribution. Thus, it can test residuals normality, assuming that the errors are normally distributed (null hypothesis). If it is about the BIO share, the probability associated with the Jarque-Bera test is 0.0000 <0.05, which indicates that null hypothesis is rejected. The distribution of the model cannot be approximated with a normal one (the errors are not normally distributed). As can be seen in Table I , the errors are not normally distributed in any of the eight cases. The normal distribution of the errors is important especially when making predictions on the basis of the estimated econometric equation.
The output includes the distribution histogram, the average, median, minimum and maximum values, the standard deviation, the coefficient of asymmetry, the kurtosis series and the Jarque-Bera test. Also, the errors average has a very low value, which means that the analysis can be substantiated on the estimated model.
Moreover, for the estimated shares portfolio, we noticed that the probability associated with the Jarque-Bera test to the significance threshold of 5% occurs for the SCD share (0,0027). This is important for the values distribution to be normal. The graphical representation of regression is captured in the Fig. 5 .
The portfolio of shares from the Romanian pharmaceutical industry presented in this work highlights some issues based on the different investment decisions which can be made. Thus, taking into account the excess risk brought to a well diversified portfolio, if the weight of one share increases by one percentage point (the value of β), then the stocks with a high value of the coefficient β are relatively cheaper for investors.
In conclusion, the BIO stock trading, with a coefficient of 0.9257 and RMAH with a coefficient of 0.9749 respectively, are relatively cheap compared to other stocks, especially with the action FITO, whose coefficient β is the lowest of the portfolio (0.1373). As the risk indicator beta (β) estimated for each share is lower than zero, it can be concluded that it is about a low risk portfolio. 
